SAFFRON-103: a phase 1b study of the safety and efficacy of sitravatinib combined with tislelizumab in patients with locally advanced or metastatic non-small cell lung cancer
Jun Zhao(Beijing Institute of Technology), Yi‐Long Wu(Guangdong Academy of Medical Sciences), Jiuwei Cui(Jilin University), Hongming Pan(Sir Run Run Shaw Hospital), Zhehai Wang(Shandong Tumor Hospital), Lifeng Wang(Chinese Academy of Tropical Agricultural Sciences), Daphne Day(Monash Health), Yanyan Peng(BeiGene (China)), Qing Zhou(Jiangnan University), Meili Sun(Jinan Central Hospital), Juan Zhang(Fujian Medical University), Bo Gao(China Aerospace Science and Technology Corporation), Hui Li(Shandong Tumor Hospital), Xinmin Yu(Zhejiang Cancer Hospital), Qian Chu(Tongji Hospital), Jingxun Wu(First Affiliated Hospital of Xiamen University), Yunpeng Liu(Shenyang Institute of Automation), Mark Voskoboynik(Monash University), Zhiyong Ma(Zhengzhou University), Dingzhi Huang(Tianjin Medical University Cancer Institute and Hospital)
Cited by 21
Related Papers
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k